NCT05263453 2023-05-31HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K MutationShanghai Kechow Pharma, Inc.Phase 2 Unknown104 enrolled
NCT02036086 2022-10-27Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node MetastasesSunnybrook Health Sciences CentrePhase 2 Unknown24 enrolled